- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00859937
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the objective response rate (complete response plus partial response) of dasatinib in adenoid cystic carcinoma (ACC).
II. Determine the progression-free survival of dasatinib in ACC.
SECONDARY OBJECTIVES:
I. Determine the duration of response. II. Determine the stable disease rate and duration of stable disease. III. Determine progression-free survival. IV. Determine the median survival. V. Determine the overall survival. VI. Determine the safety and tolerability.
TERTIARY OBJECTIVES:
I. To examine biomarkers that relate to SRC proto-oncogene, non-receptor tyrosine kinase (Src) signal transduction and to correlate these biomarkers with clinical response to dasatinib in ACC and non-ACC malignant salivary gland tumors (MSGT).
II. Determine if activating mutations in platelet-derived growth factor alpha polypeptide (PDGFA) and KIT are associated with response in ACC.
OUTLINE:
Patients receive dasatinib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed at 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T8
- CHUM-Hotel Dieu de Montreal
-
-
-
-
California
-
Beverly Hills, California, United States, 90211-1850
- Tower Cancer Research Foundation
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Merced, California, United States, 95340
- Mercy UC Davis Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Evanston, Illinois, United States, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Harvey, Illinois, United States, 60426
- Ingalls Memorial Hospital
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates Limited
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Peoria, Illinois, United States, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, United States, 62702
- Central Illinois Hematology Oncology Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
South Bend, Indiana, United States, 46628
- Northern Indiana Cancer Research Consortium
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland/Greenebaum Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
Saint Joseph, Michigan, United States, 49085
- Oncology Care Associates PLLC
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Mercy Hospital Saint Louis
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center - Moses Campus
-
Bronx, New York, United States, 10466
- Montefiore Medical Center-Wakefield Campus
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert and The Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed malignant salivary gland tumor (MSGT), including one of the following histologic subtypes:
Adenoid cystic carcinoma (ACC) with c v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (Kit) overexpression or non-ACC MSGT that is not amenable to potentially curable surgery or radiation
- c-KIT overexpression in ACC patients is defined as cluster of differentiation (CD) 117 staining by immunohistochemistry (IHC) in 25% of tumor cells
- No stipulation for c-KIT overexpression is not required for non-ACC MSGT patients
- Patients must have radiographically measurable disease; radiographically measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan
- Patients must have evidence of disease progression (objective growth of existing tumors) within 4 months of study entry
No known brain metastases, unless patient meets both of the following criteria:
- Neurologic status stable for >= 8 weeks after completion of definitive local therapy (surgery or radiotherapy)
- No neurologic dysfunction that would confound study results
- Life expectancy greater than 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 OR Karnofsky performance status (PS) >= 60%
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelet >= 100,000/mcL
- Hemoglobin >= 9 g/dL
- Serum calcium =< 12.0 mg/dL
- Total serum bilirubin within normal institutional limits
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; all women of childbearing potential must have a negative pregnancy test prior to receiving dasatinib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; at least 4 weeks must have elapsed since any major surgery
- Patients may not be receiving any other investigational agents
- No prior treatment with any other targeted agents that inhibit vascular endothelial growth factor receptor (VEGFR), Breakpoint cluster region (BCR) ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL), c-Src, c-KIT, platelet-derived growth factor (PDGF) beta receptor, or ephrin type-A receptor 2 (EPHA2) (e.g., imatinib mesylate)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib
- Patients with corrected QT interval (QTc) prolongation (defined as a QTc interval equal to or greater than 500 msec), serious ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia greater than or equal to 3 beats in a row) or other significant echocardiogram (ECG) abnormalities are excluded
- Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for intravenous [IV] alimentation, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded
Patients with any of the following conditions are excluded:
- Serious or non-healing wound, ulcer, or bone fracture
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscesses within the past 28 days
- Any history of cerebrovascular accident (CVA) or transient ischemic attack within the past 12 months
- History of myocardial infraction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 6 months
- History of pulmonary embolism within the past 12 months
- Ejection fraction less than institutional normal by echocardiograph (only required for patients with a known history of congestive heart failure, low ejection fraction, or clinical symptoms/findings consistent with congestive heart failure)
- Patients taking medications that are potent inducers or inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) liver enzyme will be determined following a review of their case by the Principal Investigator; every effort should be made to switch patients taking such agents or substances to other medications
- Patients with known brain metastases should be excluded; patients with brain metastases with stable neurologic status following local therapy (surgery or radiation) for at least 8 weeks from definitive therapy and without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events are eligible for participation; patients cannot be receiving enzyme inducing anti-convulsants including carbamazepine, phenobarbital, and phenytoin
- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements are ineligible
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
- Patients who have an active pleural or pericardial effusion of any grade
- Diagnosis of any second malignancy within the last 5 years; basal cell carcinoma, squamous cell skin cancer, stage I carcinoma fully treated, or in situ carcinoma that have been adequately treated with no evidence of recurrent disease for 12 months will be eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive dasatinib PO BID on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: Up to 2 months
|
Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence.
Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
|
Up to 2 months
|
Progression-free Survival
Time Frame: up to 5 years
|
Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Up to 5 years
|
Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.
|
Up to 5 years
|
Changes in Laboratory Correlates
Time Frame: Baseline and 4 weeks
|
Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests.
The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test.
The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival.
|
Baseline and 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stuart Wong, University of Chicago Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Salivary Gland Diseases
- Mouth Neoplasms
- Carcinoma
- Recurrence
- Carcinoma, Adenoid Cystic
- Salivary Gland Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Dasatinib
Other Study ID Numbers
- NCI-2009-01165 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA014599 (U.S. NIH Grant/Contract)
- N01CM00071 (U.S. NIH Grant/Contract)
- N01CM00038 (U.S. NIH Grant/Contract)
- N01CM00032 (U.S. NIH Grant/Contract)
- CDR0000636685
- UCCRC-16691B
- 16691B (Other Identifier: University of Chicago Comprehensive Cancer Center)
- 8271 (CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Salivary Gland Carcinoma
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)Active, not recruitingMajor Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | High-grade Salivary Gland Carcinoma | High-grade Salivary Gland Mucoepidermoid Carcinoma | Low-grade Salivary Gland Carcinoma | Low-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell... and other conditionsCanada
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma | Locally Advanced Salivary Gland CarcinomaUnited States
-
National Cancer Institute (NCI)Southwest Oncology GroupCompletedRecurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Salivary Gland Cancer | Stage IV Adenoid Cystic Carcinoma of the Oral Cavity | Stage IV Salivary Gland Cancer | Salivary Gland Adenoid Cystic...United States
-
Mayo ClinicRecruitingRecurrent Salivary Gland Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer | High-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell Tumor | Salivary Gland Adenocarcinoma | Salivary Gland Poorly Differentiated CarcinomaUnited States
-
Ontario Clinical Oncology Group (OCOG)Novartis PharmaceuticalsCompletedRecurrent Adenoid Cystic Carcinoma of the Salivary Glands | Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Salivary Gland Cancers | ACCCanada
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Cancer AJCC v7 | Stage IVB Major Salivary Gland Cancer AJCC v7 | Stage IVC Major Salivary Gland Cancer AJCC v7 | Salivary Gland Adenoid Cystic Carcinoma | Recurrent Oral Cavity Adenoid Cystic Carcinoma | Stage IVA Oral Cavity... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Cancer AJCC v7 | Stage IVB Major Salivary Gland Cancer AJCC v7 | Stage IVC Major Salivary Gland Cancer AJCC v7 | Tongue Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Recurrent Oral Cavity Adenoid Cystic Carcinoma | Stage... and other conditionsUnited States, Canada
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States